TY - JOUR
T1 - Small cell lung cancer in the young
T2 - Characteristics, diagnosis and outcome data
AU - Jiang, Shiyu
AU - Hao, Xuezhi
AU - Li, Junling
AU - Hu, Xingsheng
AU - Xiao, Zefen
AU - Wang, Hongyu
AU - Wang, Yan
AU - Sun, Yan
AU - Shi, Yuankai
N1 - Funding Information:
informationNational Key Technology Support Program, Grant/Award Number: 2014BAI09B01.National Key Technology Support Program [grant number 2014BAI09B01]. We thank the patients, their families and all investigators who participated in the study.
Funding Information:
This study was primarily funded by grants from the National Key Technology Support Program [grant number 2014BAI09B01]. We thank the patients, their families and all investigators who participated in the study.
Publisher Copyright:
© 2018 John Wiley & Sons Ltd
PY - 2019/2
Y1 - 2019/2
N2 - Background: Patients with small cell lung cancer (SCLC) younger than 40 years are limited in number. Our research aimed to assess the characteristics, diagnosis and outcomes of this patient population. Methods: Records of patients under the age of 40 with SCLC at the Chinese Academy of Medical Sciences between January 2006 and December 2015 were reviewed and evaluated. Results: One hundred and three patients (67.0% limited stage, 33.0% extensive stage) were included, along with 54 (52.4%) never-smokers. The median diagnostic interval and the median survival time (MST) were 51.0 days and 24.0 months, respectively. A total of 41 (39.8%) patients claimed to have undergone antibiotic treatment before diagnosis, with a median duration of 2 weeks. In univariate analysis, survival was better for the limited stage group than the extensive stage group (MST, 28.0 vs. 13.0 months, P < 0.0001). Also, patients who received concurrent radiochemotherapy had better survival than those who received chemotherapy alone (MST, 29.0 vs. 18.0 months, P = 0.001). Patients with antibiotic treatment before SCLC diagnosis have worse prognosis than those without (MST, 21.0 vs. 27.0 months, P = 0.008). Moreover, a timely diagnosis (≤1 month) exerted a positive impact on the overall survival in limited stage patients (48.0 vs. 26.0 months, P = 0.047) and on progression-free survival in extensive stage patients (6.0 vs. 3.0 months, P = 0.030). Multivariate analysis suggested that disease stage, history of antibiotic treatment before SCLC diagnosis and performance status independently correlated with survival. Conclusion: Our study identified distinct characteristics and prognostic factors of SCLC patients under 40 years. More timely care may improve patient prognosis.
AB - Background: Patients with small cell lung cancer (SCLC) younger than 40 years are limited in number. Our research aimed to assess the characteristics, diagnosis and outcomes of this patient population. Methods: Records of patients under the age of 40 with SCLC at the Chinese Academy of Medical Sciences between January 2006 and December 2015 were reviewed and evaluated. Results: One hundred and three patients (67.0% limited stage, 33.0% extensive stage) were included, along with 54 (52.4%) never-smokers. The median diagnostic interval and the median survival time (MST) were 51.0 days and 24.0 months, respectively. A total of 41 (39.8%) patients claimed to have undergone antibiotic treatment before diagnosis, with a median duration of 2 weeks. In univariate analysis, survival was better for the limited stage group than the extensive stage group (MST, 28.0 vs. 13.0 months, P < 0.0001). Also, patients who received concurrent radiochemotherapy had better survival than those who received chemotherapy alone (MST, 29.0 vs. 18.0 months, P = 0.001). Patients with antibiotic treatment before SCLC diagnosis have worse prognosis than those without (MST, 21.0 vs. 27.0 months, P = 0.008). Moreover, a timely diagnosis (≤1 month) exerted a positive impact on the overall survival in limited stage patients (48.0 vs. 26.0 months, P = 0.047) and on progression-free survival in extensive stage patients (6.0 vs. 3.0 months, P = 0.030). Multivariate analysis suggested that disease stage, history of antibiotic treatment before SCLC diagnosis and performance status independently correlated with survival. Conclusion: Our study identified distinct characteristics and prognostic factors of SCLC patients under 40 years. More timely care may improve patient prognosis.
KW - diagnosis
KW - small cell lung cancer
KW - survival
KW - time
KW - young adult
UR - http://www.scopus.com/inward/record.url?scp=85060685159&partnerID=8YFLogxK
U2 - 10.1111/crj.12986
DO - 10.1111/crj.12986
M3 - Article
C2 - 30586232
AN - SCOPUS:85060685159
VL - 13
SP - 98
EP - 104
JO - Clinical Respiratory Journal
JF - Clinical Respiratory Journal
SN - 1752-6981
IS - 2
ER -